Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms

About this episode

The episode discusses emerging therapeutic strategies for systemic lupus erythematosus and psoriatic arthritis, focusing on nipocalimab and deucravacitinib.

In this episode of Joint Ventures , hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared goal of greater precision in immune modulation.

People in this episode

Hosts: Jack Arnold, MBBS, PhD, Rihards Buss, MBBS

Topics covered

• therapeutic strategies
• systemic lupus erythematosus
• psoriatic arthritis
• immune modulation
• Fc receptor blockade
• tyrosine kinase 2 inhibition

Keywords

• nipocalimab
• deucravacitinib
• systemic lupus erythematosus
• psoriatic arthritis
• immune modulation
• therapeutic strategies

Mentioned in this episode

Organizations: University of Leeds, Freeman Hospital

Products: nipocalimab, deucravacitinib

More episodes of HCPLive Podcasts

• Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS · May 28, 2026 · 23 min